Menopozda Hormon Replasman Tedavisi

Harding FE. The Oral Treatment of Ovarian Deficiency with Conjugated Estrogens-equins. West J Surg Obstet Gynecol . 1944;52–31.

O’Dowd MJ., Philipp EE. The History of Obstetric and Gynaecology . New York: The Parthenon Publishing Group; 1996.

Parkes AS. The rise of reproductive endocrinology, 1926-1940. J Endocrinol. 1966 Mar;34(3):xx–xxxii.

Speroff L, STH, PL, SE,. Klinik jinekolojik endokrinoloji ve infertilite. 9th ed. Ankara: Güneş Tıp Kitabevleri; 2020.

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995 Jan 18;273(3):199–208.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–13.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–33.

North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012 Mar;19(3):257–71.

Geiger PJ, Eisenlohr-Moul T, Gordon JL, Rubinow DR, Girdler SS. Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms. Menopause. 2019 Nov;26(11):1318–23.

Berek S. Jonathan. Berek & Novak Jinekoloji. Erk Ahmet DF, editor. Nobel Tıp Kitapevi; 2017.

Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am. 1994 Jun;21(2):271–97.

Jurgens RW, Downey LJ, Abernethy WD, Cutler NR, Conrad J. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol. 1992 Aug;167(2):459–60.

O’Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9S):18S-24S.

Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982 Nov 1;144(5):511–8.

Dincer Cengiz S., Caglar G.S. Menopoz Multidisipliner Yaklaşım. 2016. 155–171 p.

Stanczyk FZ, Winer SA, Foidart JM, Archer DF. Comparison of estrogenic components used for hormonal contraception. Contraception. 2024 Feb;130:110310.

Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–204.

Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007;14(6):985–94.

Archer DF, EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2003;10(6):516–21.

Simon JA, ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006;13(2):222–31.

Castelo-Branco C, Martínez de Osaba MJ, Vanrezc JA, Fortuny A, González-Merlo J. Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas. 1993 Sep;17(2):101–11.

Genazzani AR, Monteleone P, Giannini A, Simoncini T. Hormone therapy in the postmenopausal years: Considering benefits and risks in clinical practice. Hum Reprod Update. 2021 Nov 1;27(6):1115–50.

Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer M V. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994 Sep;62(3):485–90.

Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab. 2008 Dec;93(12):4567–75.

ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstetrics and gynecology. 2014 Jan;123(1):202–16.

North American Menopause Society. The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65. Menopause. 2015 Jul;22(7):693.

“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767–94.

Haimov-Kochman R, Barak-Glantz E, Arbel R, Leefsma M, Brzezinski A, Milwidsky A, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause. 2006;13(3):370–6.

Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause. 2009;16(3):494–9.

Grady D, Ettinger B, Tosteson ANA, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstetrics and gynecology. 2003 Dec;102(6):1233–9.

Harding FE. The Oral Treatment of Ovarian Deficiency with Conjugated Estrogens-equins. West J Surg Obstet Gynecol . 1944;52–31.

O’Dowd MJ., Philipp EE. The History of Obstetric and Gynaecology . New York: The Parthenon Publishing Group; 1996.

Parkes AS. The rise of reproductive endocrinology, 1926-1940. J Endocrinol. 1966 Mar;34(3):xx–xxxii.

Speroff L, STH, PL, SE,. Klinik jinekolojik endokrinoloji ve infertilite. 9th ed. Ankara: Güneş Tıp Kitabevleri; 2020.

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995 Jan 18;273(3):199–208.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–13.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321–33.

North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012 Mar;19(3):257–71.

Geiger PJ, Eisenlohr-Moul T, Gordon JL, Rubinow DR, Girdler SS. Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms. Menopause. 2019 Nov;26(11):1318–23.

Berek S. Jonathan. Berek & Novak Jinekoloji. Erk Ahmet DF, editor. Nobel Tıp Kitapevi; 2017.

Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am. 1994 Jun;21(2):271–97.

Jurgens RW, Downey LJ, Abernethy WD, Cutler NR, Conrad J. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol. 1992 Aug;167(2):459–60.

O’Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9S):18S-24S.

Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982 Nov 1;144(5):511–8.

Dincer Cengiz S., Caglar G.S. Menopoz Multidisipliner Yaklaşım. 2016. 155–171 p.

Stanczyk FZ, Winer SA, Foidart JM, Archer DF. Comparison of estrogenic components used for hormonal contraception. Contraception. 2024 Feb;130:110310.

Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–204.

Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007;14(6):985–94.

Archer DF, EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause. 2003;10(6):516–21.

Simon JA, ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006;13(2):222–31.

Castelo-Branco C, Martínez de Osaba MJ, Vanrezc JA, Fortuny A, González-Merlo J. Effects of oophorectomy and hormone replacement therapy on pituitary-gonadal function. Maturitas. 1993 Sep;17(2):101–11.

Genazzani AR, Monteleone P, Giannini A, Simoncini T. Hormone therapy in the postmenopausal years: Considering benefits and risks in clinical practice. Hum Reprod Update. 2021 Nov 1;27(6):1115–50.

Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer M V. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994 Sep;62(3):485–90.

Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab. 2008 Dec;93(12):4567–75.

ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstetrics and gynecology. 2014 Jan;123(1):202–16.

North American Menopause Society. The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65. Menopause. 2015 Jul;22(7):693.

“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767–94.

Haimov-Kochman R, Barak-Glantz E, Arbel R, Leefsma M, Brzezinski A, Milwidsky A, et al. Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause. 2006;13(3):370–6.

Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause. 2009;16(3):494–9.

Grady D, Ettinger B, Tosteson ANA, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstetrics and gynecology. 2003 Dec;102(6):1233–9.